title: Standards of care and novel approaches in the management of glioblastoma multiforme.
abstract: Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. Standard therapeutic approaches provide modest improvement in the progression-free and overall survival, necessitating the investigation of novel therapies. We review the standard treatment options for GBM and evaluate the results obtained in clinical trials for promising novel approaches, including the inhibition of angiogenesis, targeted approaches against molecular pathways, immunotherapies, and local treatment with low voltage electric fields.
authors.affiliation: Department of Clinical Neuroscience, Lausanne University Hospital, Lausanne 1011, Switzerland. andreas.hottinger@gmail.com.
authors.forename: Andreas F
authors.initials: AF
authors.lastname: Hottinger
authors.forename: Roger
authors.initials: R
authors.lastname: Stupp
authors.forename: Krisztian
authors.initials: K
authors.lastname: Homicsko
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000628:therapy*; D019496:Cancer Vaccines / Q000627:therapeutic use; D004599:Electric Stimulation Therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000077156:Gefitinib; D005909:Glioblastoma / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D011799:Quinazolines / Q000627:therapeutic use; D012910:Snake Venoms / Q000627:therapeutic use; D059039:Standard of Care; D022223:Vaccines, Subunit / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D019496:Cancer Vaccines; D011799:Quinazolines; D012910:Snake Venoms; D022223:Vaccines, Subunit; D000068258:Bevacizumab; C422910:Cilengitide; D066246:ErbB Receptors; C558237:rindopepimut; D000077156:Gefitinib